EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of the Anti-Toxoplasma gondii Potential of Loratadine

Stephanie Ortega Alves, Ingrid de Oliveira Dias, Gabriel Candido Moura iD, Samuel Cota Teixeira iD, Juliana Quero Reimão iD

Pathogens · 22.07.2026 · 15 (7) · 773

DOI: 10.3390/pathogens15070773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 22.07.2026. Verfasst von Stephanie Ortega Alves und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (Lab. PARASITTOS), …. Hauptthemen laut MEDLINE: Toxoplasma, Loratadine, Toxoplasmosis, Antiprotozoal Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeicoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toxoplasmosis remains a major global health concern, particularly in immunocompromised individuals and pregnant women, while currently available therapies are associated with significant toxicity and limited efficacy against chronic infection. Drug repurposing represents an attractive strategy for the identification of safer and more effective anti-Toxoplasma gondii agents. This study investigated the antiparasitic potential of loratadine, a second-generation antihistamine, using an integrated in silico, in vitro, and in vivo approach. The anti-T. gondii activity of loratadine was evaluated through β-galactosidase-based proliferation assays, reversibility assays, and experiments using pretreated tachyzoites. In vivo efficacy was assessed in murine models of acute and chronic toxoplasmosis. Disease progression, survival, parasite burden, and cerebral cyst formation were analyzed following treatment. Loratadine inhibited the intracellular proliferation of T. gondii tachyzoites in a concentration-dependent manner and induced partially irreversible effects on parasite viability after drug withdrawal. Pretreatment of extracellular tachyzoites produced limited effects, suggesting that loratadine predominantly acts during the intracellular stage of infection. In the acute toxoplasmosis model, loratadine treatment delayed disease progression, prolonged animal survival, and significantly reduced the number of tachyzoites recovered from the peritoneal cavity. In the chronic infection model, treatment significantly decreased both the number and size of cerebral cysts, although these findings do not demonstrate cyst eradication or direct bradyzoite killing. Despite its measurable biological activity, loratadine exhibited a relatively low in vitro selectivity index, highlighting the need for further optimization. These exploratory findings identify loratadine as a promising lead compound (hit) for further optimization rather than an immediately translatable therapeutic candidate. Additional medicinal chemistry, pharmacokinetic, mechanistic, and confirmatory preclinical studies will be required to determine its potential for anti-T. gondii drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaLoratadineToxoplasmosisAntiprotozoal AgentsAnimalsMiceFemaleDisease Models, AnimalHumansDrug Repositioning

Stichwörter der Autor:innen

Toxoplasma gondiiantihistaminesdrug repurposingin vivo efficacyloratadinetoxoplasmosis

Substanzen

LoratadineAntiprotozoal Agents

Autor:innen und Institutionen

  • Laboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (Lab. PARASITTOS), Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, Brazil.
  • Laboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia 38405-320, Brazil.

ORCID-Profile: Gabriel Candido Moura, Samuel Cota Teixeira, Juliana Quero Reimão

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeicoamento de Pessoal de Nível Superior
  • São Paulo State Research Support Foundation
  • Brazilian National Research Council

Zitieren

APA

Alves, S. O., Dias, I. O., Moura, G. C., Teixeira, S. C., & Reimão, J. Q. (2026). Investigation of the Anti-Toxoplasma gondii Potential of Loratadine. Pathogens, 15(7), 773. https://doi.org/10.3390/pathogens15070773

Vancouver

Alves SO, Dias IO, Moura GC, Teixeira SC, Reimão JQ. Investigation of the Anti-Toxoplasma gondii Potential of Loratadine. Pathogens. 2026;15(7):773. doi:10.3390/pathogens15070773

BibTeX
@article{Alves2026,
  author = {Alves, Stephanie Ortega and Dias, Ingrid de Oliveira and Moura, Gabriel Candido and Teixeira, Samuel Cota and Reimão, Juliana Quero},
  title = {Investigation of the Anti-Toxoplasma gondii Potential of Loratadine},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {773},
  doi = {10.3390/pathogens15070773}
}
Kostenlos starten →